We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
MRESVIA Moderna Australia Pty Ltd
Product name
MRESVIA
Sponsor
Accepted date
Jun-2025
Active ingredients
respiratory syncytial virus F protein mRNA (nucleoside modified)
Proposed indication
mRESVIA is a vaccine for the prevention of respiratory syncitial virus (RSV). It is administered to adults 18 through 59 years of age who are at increased risk of RSV spreading to lower parts of the respiratory system, such as the lungs.
Application type
C (new indication)
Publication date
Jun-2025